Indonesian Presidential Candidate Exploring Potential of Tobacco Downstream in Central Java

Regulations by 2FIRSTS.ai
Dec.27.2023
Indonesian Presidential Candidate Exploring Potential of Tobacco Downstream in Central Java
Ganjar Pranowo, Indonesian presidential candidate, explores the potential for tobacco downstreaming in Klaten, Central Java.

According to Indonesian media outlet ANTARA's report on December 27th, presidential candidate Ganjar Pranowo discussed the possibility of enhancing downstream research on tobacco during his visit to Warehouse 45 in Klaten Regency, Central Java. The aim is to explore the potential of transforming tobacco into various products beyond cigarettes, such as cosmetics and pharmaceuticals.

 

According to a report by ANTARA on November 23rd, Pranowo visited Kraden directly to gather insights from farmers, entrepreneurs, and the local community regarding tobacco products. He stated that as long as there is research, we can use tobacco for any purpose. He hopes that tobacco farmers in Kraden can learn from certain regions in Central Java, which are able to export high-quality tobacco and make it a major product in the agricultural sector.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.
Nov.18 by 2FIRSTS.ai
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
The European Patent Office’s Board of Appeal upheld British American Tobacco’s Nicoventures Trading Ltd. vape patent, rejecting Philip Morris International’s objections. The board ruled that the patent’s use of predefined heater activation parameters not based on user puffs was novel and valid.
Nov.10
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
BAT Japan to raise prices of glo heated-tobacco sticks by about 4%–5%
BAT Japan to raise prices of glo heated-tobacco sticks by about 4%–5%
BAT Japan said it will raise retail prices by ¥20 (about $0.13) per pack for 16 glo heated-tobacco stick brands—11 Lucky Strike and five Kent—effective January 1, 2026. The company will also lift prices for 12 VELO nicotine pouch brands by ¥20–¥40 per pack from December 1, 2025.
Oct.21 by 2FIRSTS.ai
Fires at Two Cumbria Recycling Centres Spur Warning on Safe Disposal of Batteries and Vapes
Fires at Two Cumbria Recycling Centres Spur Warning on Safe Disposal of Batteries and Vapes
Two recycling centres in Cumbria recently experienced fires that are believed to have been caused by improperly discarded batteries or vapes. Although the blazes were quickly extinguished and no injuries were reported, both sites were evacuated. Cumberland Council reminded residents that batteries and vapes must never be placed in general kerbside waste bins and should be taken to designated recycling points. In a separate incident, a fire at the Flusco household waste recycling centre was thoug
Sep.30 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21